DrugPatentWatch Database Preview
Biologic Drugs With Dosage Form: INJECTABLE;INTRAVENOUS
» See Plans and Pricing
Details for Dosage Type: INJECTABLE;INTRAVENOUS
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021629 | 001 | 2005-12-20 | Start Trial | Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE) | 2017-06-20 | DISCN | company | |
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021629 | 001 | 2005-12-20 | Start Trial | SDG, Inc. (Cleveland, OH) | 2040-03-31 | DISCN | search | |
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021629 | 001 | 2005-12-20 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | DISCN | search | |
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021629 | 001 | 2005-12-20 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2029-05-13 | DISCN | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |